Top Story

FDA approves rosuvastatin for use in youth aged 8 to 17 with HeFH

November 30, 2015

AstraZeneca announced that the FDA has approved rosuvastatin to reduce total cholesterol, LDL and apolipoprotein B in pediatric patients aged 8 to 17 years with heterozygous familial hypercholesterolemia.

According to the company, rosuvastatin (Crestor, AstraZeneca) can now be administered to that patient population after failure of an adequate-length attempt at control through diet if LDL > 190 mg/dL or if LDL > 160 mg/dL and the patient has a family history of CVD or at least two other risk factors for CVD.

SupplementPublication Exclusive

Research highlights progress of PROMISE, controversies in treatment of chronic angina

Cardiology Today, November 2015
New-onset stable chest pain or angina in those without diagnosed heart disease affects about 4 million Americans per year. In response, the editors of Cardiology
In the Journals

Novel oral anticoagulants may reduce stroke, bleeding risk in patients with renal impairment

November 30, 2015
In patients with mild or moderate renal impairment, the use of novel oral anticoagulants appears to confer reduced risks for stroke or systemic embolism, as well as for…
In the Journals

Stroke, CHD more likely in black adults with depressive symptoms

November 30, 2015
New data from the Jackson Heart Study indicate that blacks with symptoms of major depression are at increased risk for incident stroke and may be at increased risk for…
Meeting News Coverage

Patients with PAD who receive DES show positive outcomes at 2 years

November 30, 2015
LAS VEGAS — A drug-eluting stent benefited patients with lesions in the superficial femoral artery at 2 years, according to findings presented at VIVA…
More News Headlines »

Antiplatelet Agents for Secondary Prevention of Thrombotic Cardiovascular Events in Patients with History of Cerebrovascular Disease

This activity is supported by an educational grant from Merck & Co., Inc.

In this CME activity, Dr. David Morrow discusses the use of antiplatelet agents for secondary prevention of thrombotic…
More »
Meeting News Coverage Video

VIDEO: Liraglutide fails to improve HF outcomes in FIGHT trial

November 28, 2015
More »

Navigating a New Era of Personalized Type 2 Diabetes Care: Taking the Road Less Traveled

This activity is supported by an educational grant from Salix, A Dvision of Valeant Pharmaceuticals North America, LLC.

In the United States, over 29 million people have diabetes, of which approximately 95% of cases are type 2 diabetes…
More »
morganatic-roan morganatic-roan